Home › Funds › Propel Bio Management, LLC › PALI
Propel Bio Management, LLC position in PALI
PALISADE BIO INC · Health Care
Propel Bio Management, LLC reported holding 2,224,189 shares of PALI (PALISADE BIO INC) in its Q3 2026 13F filing — a position valued at US$3.0M, representing 1.59% of its reported portfolio and ranking #20 among its reported holdings. Propel Bio Management, LLC has disclosed PALI holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's PALI position evolved
Propel Bio Management, LLC first disclosed a stake in PALI in Q1 2026 at 1,115,000 shares (US$2.0M). The position peaked in Q2 2026 at 2,582,388 shares, worth US$5.4M. Across 3 filings, Propel Bio Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,224,189 shares valued at US$3.0M — a reduction of -358,199 shares quarter over quarter.. Notable position changes include a 132% increase in Q2 2026 (shares fell 35% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 1.11M | $2.00M | New |
| Q2 2026 | 2.58M | $5.40M | Add |
| Q3 2026 | 2.22M | $3.00M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PALI and 13F data
PALI (PALISADE BIO INC) is a Health Care company. 94 other funds we track also report a position in PALI — the largest reported positions include Soleus Capital Management, L.P. (US$27.3M), B Group, Inc. (US$23.9M), Octagon Capital Advisors LP (US$21.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PALI
- Soleus Capital Management, L.P. 13.06M sh · $27.30M · Q2 2026
- B Group, Inc. 11.41M sh · $23.86M · Q2 2026
- Octagon Capital Advisors LP 10.28M sh · $21.48M · Q2 2026
- Boxer Capital Management, LLC 4.80M sh · $10.03M · Q2 2026
- Squadron Capital Management LLC 3.00M sh · $6.27M · Q2 2026
- GREAT POINT PARTNERS LLC 2.28M sh · $4.78M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 2.26M sh · $4.72M · Q2 2026
- Artia Global Partners LP 1.99M sh · $4.16M · Q2 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 1.73M sh · $3.62M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.34M sh · $3.15M · Q3 2026
- Ally Bridge Group (NY) LLC 1.23M sh · $2.57M · Q2 2026
- Creek Drive Management Group LLC 680.00K sh · $918.00K · Q3 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held PALI?
Propel Bio Management, LLC has disclosed PALI holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Propel Bio Management, LLC's current position in PALI?
As of Q3 2026, Propel Bio Management, LLC holds 2.22M shares of PALI (PALISADE BIO INC), valued at $3.00M, representing 1.59% of its reported portfolio and ranking #20.
Has Propel Bio Management, LLC been buying or selling PALI?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC reduced its position in PALI. The position peaked in Q2 2026 at 2.58M shares.
Which other funds hold PALI?
Other major institutional holders of PALI include Soleus Capital Management, L.P., B Group, Inc., Octagon Capital Advisors LP, among 94 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.